Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
药物研究 抗生素和抗病毒 肿瘤
/
G蛋白偶联受体/G蛋白
小分子阳性药 免疫/炎症 功能 肿瘤干细胞 前列腺癌 胰腺癌
/
CXCR
抗病毒
/ Plerixafor/普乐沙福

Plerixafor/普乐沙福 {[allProObj[0].p_purity_real_show]}

货号：A195007 同义名： AMD 3100; JM3100

Plerixafor是一种 CXCR4 受体拮抗剂，能够抑制 CXCL12 介导的趋化作用，IC50 分别为 44 nM 和 5.7 nM。

Plerixafor/普乐沙福 化学结构 CAS号：110078-46-1
Plerixafor/普乐沙福 化学结构
CAS号：110078-46-1
Plerixafor/普乐沙福 3D分子结构
CAS号：110078-46-1
Plerixafor/普乐沙福 化学结构 CAS号：110078-46-1
Plerixafor/普乐沙福 3D分子结构 CAS号：110078-46-1
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} 		{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Plerixafor/普乐沙福 纯度/质量文件 产品仅供科研

货号：A195007 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
• Cell, 2025. Ambeed. [ A122167 ]
• Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
• Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
• Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >
产品名称 CXCR1 ↓ CXCR2 ↓ CXCR4 ↓ 其他靶点 纯度
Reparixin ✔ 99%+
SB225002 +++

CXCR2, IC50: 22 nM

 		99%+
Plerixafor ++

CXCR4, IC50: 44 nM

 		99%
AMD 3465 6HBr ✔ 98%
WZ811 ++++

CXCR4, EC50: 0.3 nM

 		99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Plerixafor/普乐沙福 生物活性

靶点

  • CXCR4

    CXCR4, IC50:44 nM
描述 Through binding with CC- and CXC-chemokines, CCR and CXCR, the subsets of the chemokine receptor family can trigger an intracellular signal transduction cascade, thus mediating the recruitment of immune cells to the in£ammation or infection sites and implicated in several immuno-related disease states, organogenesis, angiogenesis and tumor growth and metastasis. AMD3100 is a selective antagonist of CXCR4 with IC50 values ranging in 0.01-0.13μg/ml for antagonizing SDF-1, but not itself, activated calcium flux in different cells tested, including CXCR4-transfected U87 and CD4 cells, freshly isolated PBMCs, SupT1, THP-1, HSB-2, Molt-4 and L1210 cells. The inhibitory effect of AMD3100 against the induced endocytosis of CXCR4 is selectively SDF-1-dependent but not phorbol ester. Pre-incubated with AMD3100 at concentration of 0.04, 0.2, 1, 5 and 25μg/ml could dose-dependently inhibit the SDF-1-induced (200 ng/ml) chemotaxis of human PBMCs[1]. In vivo study showed that intraperitoneal injection with 5mg/kg AMD3100 can alter the potential of mesenchymal stem cells mobilization induced by different growth factors, including IGF-1, SCF, PDGF and VEGF, in mice, which may be mediated through Akt/PI3K, MEK1/2-Erk1/2 and smad2/3 as key signaling pathways[2].
作用机制 Not found

Plerixafor/普乐沙福 细胞实验

Cell Line
Concentration Treated Time Description References
KU812F cells 50 μM 3 h Reduced adhesion of CML cells to BM microenvironment components Leukemia. 2012 May;26(5):985-90.
KU812F cells 50 μM 3 h Reduced drug resistance of CML cells to nilotinib Leukemia. 2012 May;26(5):985-90.
EJ cells 50 μM 24 h Inhibited the proliferation and migration capacity of EJ cells by blocking CXCR4 downstream signaling Sci Adv. 2023 Mar;9(9):eabq8225.
MDA-MB-231 cells 10 μg/mL 1 h To study the uptake of Plerixafor-modified nanocarriers in CXCR4-expressing MDA-MB-231 cells, results showed that Plerixafor-modified nanocarriers had a higher uptake rate in CXCR4-expressing cells compared to unmodified carriers. Biomacromolecules. 2015 Aug 10;16(8):2412-7.

Plerixafor/普乐沙福 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
Mice Radiation-induced wound healing deficit model Subcutaneous injection 5 mg/kg Single injection Plerixafor combined with G-CSF enhanced the efficacy of MSC-FMB in correcting radiation-induced wound healing deficits J Invest Dermatol. 2013 Feb;133(2):553-61
Mice Spinal cord injury model Subcutaneous injection 5 mg/kg Once daily for 3 days Plerixafor treatment increased the number of HSPCs released into the blood by more than 6-fold, with a corresponding increase in the number of HSPCs found in the spleen, and reversed the post-SCI leukopenia. Nat Commun. 2020 Jul 24;11(1):3702
Mice BCR-ABL-positive leukemia mouse model Subcutaneous injection 5 mg/kg Once daily for 10 days Reduced leukemia burden and prolonged survival Leukemia. 2012 May;26(5):985-90.
Nude mice EJ xenograft model Intravenous injection 100 μM, 100 μl Once every 2 days for a total of five times Plerixafor significantly inhibited tumor growth, with a mean tumor volume of 647±147 mm3, compared to 1086±257 mm3 in the saline group Sci Adv. 2023 Mar;9(9):eabq8225.
Rhesus macaque Rhesus gene therapy model Intravenous injection 1 mg/kg Single dose, after 5 days of G-CSF administration Mobilization of CD34+ cells for gene therapy model Nat Commun. 2023 Oct 12;14(1):6291

Plerixafor/普乐沙福 动物研究

Dose Mice[3]: 0.625 mg/kg - 10 mg/kg (s.c.) Rat[3]: 25 mg/kg (s.c.), 2 mg/kg (i.v.)
Administration s.c., i.v.
Pharmacokinetics
Animal Rats[3]
Dose 1 mg/kg
Administration s.c.
T1/2 0.1 h (absorption)
Tmax 0.5 h
AUC0-7 5410 pmol·h/ml
Cmax 3082 pmol/ml
t1/2λ1 0.9 h
AUC 5444 pmol·h/ml

Plerixafor/普乐沙福 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01164475 - Completed - -
NCT01711073 End Stage Liver DIsease Phase 1 Unknown September 2013 United States, New Jersey ... 展开 >> University of Medicine and Dentistry of New Jersey Recruiting Newark, New Jersey, United States, 07101 Contact: Baburao Koneru, MD       koneruba@umdnj.edu 收起 <<
NCT01123499 - Recruiting - United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting Bethesda, Maryland, United States, 20892 Contact: Sandra Maxwell, B.S.N.    301-402-1773    maxwells@niaid.nih.gov 收起 <<

Plerixafor/普乐沙福 参考文献

[1]Plerixafor

Plerixafor/普乐沙福 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.99mL

0.40mL

0.20mL

9.94mL

1.99mL

0.99mL

19.89mL

3.98mL

1.99mL

Plerixafor/普乐沙福 技术信息

CAS号110078-46-1
分子式C28H54N8
分子量 502.78
SMILES Code N1(CC2=CC=C(CN3CCNCCCNCCNCCC3)C=C2)CCNCCCNCCNCCC1
MDL No. MFCD05662218
别名 AMD 3100; JM3100; JKL 169; Mozobil; SDZ SID 791; SID791
运输蓝冰
InChI Key YIQPUIGJQJDJOS-UHFFFAOYSA-N
Pubchem ID 65015
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Keep in dark place, inert atmosphere, 2-8°C
溶解方案

DMSO: 1.5 mg/mL(2.98 mM)，配合低频超声，水浴加热至45℃，并调节pH至5，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

无水乙醇: 45 mg/mL(89.5 mM)，配合低频超声助溶，注意：无水乙醇开封后，易挥发，也会吸收空气中的水分，导致溶解能力下降，请避免使用开封较久的乙醇

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶
方案 一
方案 二
方案 三

Tags: Plerixafor | AMD 3100;JM3100;JKL 169;Mozobil;SDZ SID 791;SID791 | Antivirus | CXCR | AmBeed-信号通路专用抑制剂 | Plerixafor/普乐沙福 纯度/质量文件 | Plerixafor/普乐沙福 亚型比较 | Plerixafor/普乐沙福 生物活性 | Plerixafor/普乐沙福 动物研究 | Plerixafor/普乐沙福 临床数据 | Plerixafor/普乐沙福 参考文献 | Plerixafor/普乐沙福 实验方案 | Plerixafor/普乐沙福 技术信息

AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 AmBeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z